Advaxis Inc Cmn Stk (ADXS) 8.47 $ADXS Phase 1/2

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Advaxis Inc Cmn Stk (ADXS) 8.47 $ADXS

Phase 1/2 Combination Trial of AXAL and Durvalumab Completes Second Dose-Escalation Cohort
GlobeNewswire - Tue Jul 26, 7:00AM CDT
Part A expansion and Part B now enrolling for AXAL in combination with durvalumab for the treatment of advanced, recurrent or refractory HPV-associated cervical cancer and head & neck cancer
ADXS: 8.47 (+0.13)

European Medicines Agency Committee Classifies Advaxis' Axalimogene Filolisbac as an Advanced-Therapy Medicinal Product
GlobeNewswire - Mon Jul 18, 6:30AM CDT
Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, today announced that its lead Lm immunotherapy candidate, axalimogene filolisbac (AXAL), has been classified as an advanced-therapy medicinal product (ATMP) for the treatment of cervical cancer by the European Medicines Agency's Committee for Advanced Therapies (CAT).
ADXS: 8.47 (+0.13)

Advaxis to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference
GlobeNewswire - Fri Jul 08, 7:00AM CDT
Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, today announced that Daniel J. O'Connor, President, Chief Executive Officer and Director of Advaxis, will present a company overview at Cantor Fitzgerald's 2nd Annual Healthcare Conference being held July 12-13, 2016 in New York, N.Y.
ADXS: 8.47 (+0.13)

Advaxis Announces First Patient Dosed in Phase 2 Trial Evaluating AXAL in Anal Cancer
GlobeNewswire - Wed Jun 08, 7:00AM CDT
FAWCETT study named to honor Farrah Fawcett, who passed away from HPV-associated anal cancer
ADXS: 8.47 (+0.13)

Advaxis Announces Updated Data at ASCO from a Phase 2 Study of AXAL in Advanced Cervical Cancer Showing Promising Survival Rates Consistent with Earlier Reports
GlobeNewswire - Mon Jun 06, 6:00AM CDT
Durable complete response seen in a recurrent / metastatic cervical cancer patient previously treated with chemoradiation and systemic-dose chemotherapy plus bevacizumab
ADXS: 8.47 (+0.13)

Advaxis to Host Investor & Analyst Day on June 28, 2016
GlobeNewswire - Tue May 17, 7:05AM CDT
Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, today announced that they will host their annual Investor & Analyst Day, on Tuesday, June 28, 2016 at 1:30 PM EST in New York, NY.
ADXS: 8.47 (+0.13)

UPDATE - Advaxis to Present at Jefferies 2016 Healthcare Conference
GlobeNewswire - Thu May 05, 8:24AM CDT
Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, today announced that Daniel J. O'Connor, President, Chief Executive Officer and Director of Advaxis, will present a company overview at the 2016 Jefferies Healthcare Conference being held June 7-10, 2016 in New York, NY.
ADXS: 8.47 (+0.13)

Advaxis to Present at Jeffries 2016 Healthcare Conference
GlobeNewswire - Thu May 05, 7:35AM CDT
Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, today announced that Daniel J. O'Connor, President, Chief Executive Officer and Director of Advaxis, will present a company overview at the 2016 Jefferies Healthcare Conference being held June 7-10, 2016 in New York, NY.
ADXS: 8.47 (+0.13)

FDA Grants Advaxis Fast Track Designation for ADXS-HER2 for Patients with Newly-Diagnosed, Non-Metastatic, Surgically-Resectable Osteosarcoma
GlobeNewswire - Thu Apr 28, 6:05AM CDT
Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, today announced that the Food and Drug Administration (FDA) has granted Fast Track Designation for the company's immunotherapy product candidate ADXS-HER2 for patients with newly-diagnosed, non-metastatic, surgically-resectable osteosarcoma.
ADXS: 8.47 (+0.13)

Phase II Cervical Cancer Study with Advaxis' Axalimogene Filolisbac Selected for Poster Discussion Session at the 2016 ASCO Annual Meeting
GlobeNewswire - Mon Apr 25, 7:05AM CDT
Poster Discussion Sessions highlight the most clinically applicable and novel posters
ADXS: 8.47 (+0.13)

AACR Research Reception Featured Late-Breaking Poster on Lm Technology(TM) Platform
GlobeNewswire - Tue Apr 19, 8:05AM CDT
Reception included update on the Company's MINE program
ADXS: 8.47 (+0.13)

Sarcoma Foundation of America Honors Advaxis for Advancements in Immunotherapy Platform
GlobeNewswire - Wed Apr 13, 7:00AM CDT
First biotechnology company to ever receive Vision of Hope Award
ADXS: 8.47 (+0.13)

Here's Why Advaxis Inc.'s Stock Roared Higher in March
George Budwell, The Motley Fool - Motley Fool - Tue Apr 12, 3:22PM CDT
What: Shares of the clinical-state biotech Advaxis gained over 50% last month, according to data from S&P Global Market Intelligence . The main catalyst behind this monstrous surge was the news that the company's midstage study for its...
ADXS: 8.47 (+0.13)

Advaxis Combination Trial with Merck Completes First Two Dose-Escalation Cohorts
GlobeNewswire - Tue Apr 05, 7:00AM CDT
Study Evaluating ADXS-PSA Launches Third Dose-Escalation Cohort
ADXS: 8.47 (+0.13), MRK: 58.66 (unch)

Advaxis to Present at the 3rd Annual Jefferies Immuno-Oncology Summit
GlobeNewswire - Mon Apr 04, 8:05AM CDT
Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, will present at the 3rd Annual Jefferies Immuno-Oncology Summit on Friday, April 8 at the Boston Harbor Hotel.
ADXS: 8.47 (+0.13)

Advaxis Combination Trial with MedImmune Completes First Dose-Escalation Cohort
GlobeNewswire - Tue Mar 29, 6:05AM CDT
Study Commences Second Dose-Escalation Cohort
ADXS: 8.47 (+0.13)

UPDATE -- Advaxis Hosts Research Reception to Review Late-Breaking AACR Abstract
GlobeNewswire - Wed Mar 23, 7:08AM CDT
Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, today announced that the company will host a Research Reception at the American Association for Cancer Research (AACR) Annual Meeting. The Research Reception, for which registration is required, will be held at 6:30 PM CT on April 18, 2016 at the Sheraton New Orleans Hotel in New Orleans, Louisiana.
ADXS: 8.47 (+0.13)

Advaxis Hosts Research Reception to Review Late-Breaking AACR Abstract
GlobeNewswire - Wed Mar 23, 6:05AM CDT
Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, today announced that the company will host a Research Reception at the American Association for Cancer Research (AACR) Annual Meeting. The Research Reception, for which registration is required, will be held at 6:30 PM CT on April 18, 2016 at the Sheraton New Orleans Hotel in New Orleans, Louisiana.
ADXS: 8.47 (+0.13)

Survival Results with Advaxis HER2 Targeted Immunotherapy in Canine Osteosarcoma Published in Clinical Cancer Research
GlobeNewswire - Mon Mar 21, 6:05AM CDT
Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, today announced that data from a dose-escalation study of ADXS-HER2 in canine osteosarcoma (OSA) was published online March 18, 2016 in Clinical Cancer Research, a journal of the American Association for Cancer Research (AACR).
ADXS: 8.47 (+0.13)

Advaxis to Present at Barclays Global Healthcare Conference
GlobeNewswire - Mon Mar 14, 6:17PM CDT
Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, today announced that it is scheduled to present on Wednesday, March 16, 2016 at 4:20 p.m. EDT at the 2016 Barclays Healthcare Conference at the Loews Miami Beach Hotel in Miami Beach, Florida.
ADXS: 8.47 (+0.13)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

AdMaven's Mave AI: Revolutionizing Campaign Management

Updated Category News Views 106

Taking the Tedious Out of Advertising You've got to love it when technology actually makes life easier, rather than more complicated. AdMaven's latest fancy toy, the AI assistant Mave, is promising just that. It's designed to take the heavy lifting off advertisers' shoulders, especially the day-to-day grind of tweaking ad settings and monitoring performance. If you've...

Continue Reading
Loyalty Programs Cut $1500 Annually for Consumers

Updated Category News Views 56

Loyalty Programs: An Essential Tool for Households In a world where every dollar counts, retail loyalty programs have become more than just a marketing strategy—they're lifelines for American households scraping through each month. According to fresh research by the Retail Industry Leaders Association (RILA) and conducted by market research leader Circana, these...

Continue Reading
Midea's R290 Tech: Real Green Cooling Revolution?

Updated Category News Views 258

A Fresh Breeze in Sustainable Cooling In the middle of Kigali’s innovation oasis, Midea RAC stood out at MOP38, the 38th Meeting of the Parties to the Montreal Protocol, flexing its sustainable tech muscles. We're talking about their R290 air conditioning technology—a natural refrigerant with zero ozone footprint and a global warming potential of a mere three. This is...

Continue Reading
ROBOTERA Debuts XHAND 1 Pro-U in NVIDIA Demo

Updated Category News Views 145

ROBOTERA Steps Up with XHAND 1 Pro-U Move over, traditional robotics; ROBOTERA is here to shake things up with their latest marvel, the XHAND 1 Pro-U. This futuristic gadget isn't just making waves at the Conference on Robot Learning (CoRL) where Jim Fan of NVIDIA spotlighted it in his GR00T 2 demo, it's setting a new bar for robotic dexterity. Hand in Glove with Human...

Continue Reading
DarioHealth's New Research Tackles Healthcare Cost Estimation

Updated Category News Views 104

Unpacking Dario's Bold Surgical Strike at ISPOR Europe Alright, folks, DarioHealth is shaking up the stage with their new methodology that could very well carve a new path in how we size up digital healthcare savings. Presented at ISPOR Europe 2026, Dario's tactic bypasses the sluggish wait on medical claims data, instead offering an evidence-driven peek at potential...

Continue Reading
Alliance for Women in Media Champions Change in 2026

Updated Category News Views 60

A Celebration of Trailblazing Women in Media If there's one thing I've learned about strong leadership, it's that you can't fake authenticity. Today, we're tipping our hats to some genuine trailblazers. The Alliance for Women in Media (AWM) held its annual Gracies Leadership Awards, celebrating the achievements and vision of seven remarkable women. Honoring the...

Continue Reading
Lennar Faces Legal Heat Over Alleged Misleading Statements

Updated Category News Views 39

Rumbling Legal Drama with Lennar Corporation Every trader knows the uneasy feeling when a stock you're eyeing takes a surprising nosedive on some legal muck coming out of the woodwork. Well, it's Lennar Corporation's turn in the spotlight for all the wrong reasons. They're getting slapped with a class action lawsuit by investors claiming the company pulled a fast one...

Continue Reading
Caladan Partners with Anchorage for Stronger Trading

Updated Category News Views 50

Caladan and Anchorage Unite for Asset Growth Man, partnerships might just be the secret sauce we never know we need until it’s on our plate. It's a fresh day in digital trading, and Caladan just shook things up by teaming up with Anchorage Digital, bolstering their trading and settlement capabilities to satisfy the big players. If there's one thing that's hot as a...

Continue Reading
Thunes Boosts Bhutan Remittances with Instant Payments

Updated Category News Views 283

Thunes' Network Expands to Bhutan: A Game Changer I'll say one thing clear—Thunes isn't messing around. They've just opened the gates for real-time payouts to Bhutan, and it's going to be a game-changer for those living abroad who want to send money back home. Look, for years, Non-Resident Bhutanese have been diving into hoops just to get their bucks across borders....

Continue Reading
Dr. Obeng Joins WellcomeMD with Special Offer for Patients

Updated Category News Views 23

New Beginnings in Concierge Medicine In late October, WellcomeMD opened its doors to Dr. Paa-Kofi Obeng—an arrival greeted with considerable anticipation in Richmond's medical scene. This isn't just any run-of-the-mill staff addition; Dr. Obeng brings with him over a decade of experience from places like the Veterans Administration Medical Center. He's armed with a...

Continue Reading

Top 5 Most Recently Viewed Articles

Analysts Alter Predictions for Texas Instruments Earnings Release

Updated Category News Views 48

Analysts Update Forecasts for Texas Instruments Earnings Texas Instruments Incorporated (NASDAQ: TXN) is set to unveil its third-quarter earnings results, scheduled for release after the market closes on a Tuesday evening. Investors are keenly anticipating the outcome as industry buzz suggests that earnings could reflect a notable change from previous figures. Current...

Continue Reading
Iris Energy Limited: Understanding Investor Rights and Legal Options

Updated Category News Views 117

Understanding Your Rights as an Investor in Iris Energy Limited As an investor in Iris Energy Limited, it’s essential to know your rights, especially during challenging times. The legal landscape surrounding securities can be complex, and having informed legal support is crucial. Many investors are unaware of their options and the potential to recover losses stemming...

Continue Reading
McKesson Corporation Set to Release Earnings This November

Updated Category News Views 108

McKesson Corporation's Second Quarter Earnings Announcement McKesson Corporation (NYSE: MCK) is preparing to release its earnings report for the second quarter of fiscal 2025, which will happen after the market closes. Investors and stakeholders can expect to see the detailed financial results made public on a Wednesday. This announcement is a significant moment for the...

Continue Reading
Advantech's Innovations at Medical AI Solutions Conference

Updated Category News Views 122

Advantech Unveils Cutting-Edge Medical AI Solutions Advantech, a renowned global leader in industrial IoT and edge computing solutions, is excited to announce its presence at the MedTech Conference, an event that gathers leading figures in healthcare technology to discuss innovations shaping the future of patient care. Attendees will find Advantech at Booth #1007,...

Continue Reading
Canada's Defence Investment Spurs Innovation and Growth for Draganfly

Updated Category News Views 236

Canada's Defence Investment: A New Era for Technological Advancement In a bold effort to enhance national security, the Canadian government has revealed a significant long-term defence investment package worth $80 billion. This strategic move, championed by Prime Minister Mark Carney, is designed to advance technological capabilities in defence, bolster domestic...

Continue Reading